The mission of the Comprehensive Cancer Center at St. Jude Children's Research Hospital (SJCCC) is to advance cures and means of prevention for pediatric cancer: the leading cause of disease-related death in children aged 1 to 14 years. For 36 of our 50 year history, we have pursued this mission with the support of a Cancer Center Support Grant from the National Cancer Institute (NCI). We remain the only NCI designated Cancer Center that is dedicated solely to the research and treatment of pediatric malignancies. As such, we serve as a national and international resource for health care providers, children with cancer, and their families. Through the support of the American Lebanese and Syrian Associated Charities (ALSAC), a separate corporation whose sole purpose is to raise money in support of St. Jude Children's Research Hospital (SJCRH), patients are accepted without regard to race, religion or ability to pay. Seventy-five percent of the total institutional space and annual budget are invested in the SJCCC. The current application proposes five multidisciplinary research Programs that are organized with the specific intent of translating basic science discoveries into curative therapies for children with cancer, while minimizing long-term side effects: our three disease-oriented Programs focus on Developmental Biology and Solid Tumors (DBSTP), Hematological Malignancies (HMP), and Neurobiology and Brain Tumors (NBTP); our Cancer Prevention and Control Program (CPCP) strives to improve the quality of life of individuals surviving childhood cancer; and our new Cancer Genetics, Biochemistry and Cell Biology Program (CGBCBP), formed by merging our two prior basic laboratory research Programs, embeds basic cancer research within the heart of the SJCCC, facilitating direct interaction between the disease-oriented Programs and the major laboratory resources in the Center. Research by the 144 aligned members is supported by 10 Shared Resources and an outstanding clinical research infrastructure. During the previous funding period, a new Director was appointed and several enhancements were made to the overall structure, policies, and procedures of the SJCCC. 32,522 clinical trial enrollments occurred at the Center during the current funding period, of which 56% were to SJCCC investigator initiated studies. External peer reviewed trials, many which are SJCCC member-led, accounted for another 38% of enrollments. SJCCC members published more than 2,100 manuscripts during the funding period, and in the last 12 months were supported by $69.4 million in extramural funding ($57 million, peer-reviewed; $12.4 million, non-peer-reviewed).

Public Health Relevance

The five multidisciplinary research Programs and ten Shared Resources in the SJCCC work together to find cures for pediatric cancer, while minimizing the long-term side effects of treatment. With strong institutional and philanthropic support, for 50 years we have served as a national and international resource for health care providers, children with cancer, and their families. In this mission we accept patients without regard to race, religion or ability to pay.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA021765-39
Application #
9439706
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Roberson, Sonya
Project Start
1997-04-01
Project End
2019-02-28
Budget Start
2018-03-01
Budget End
2019-02-28
Support Year
39
Fiscal Year
2018
Total Cost
Indirect Cost
Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105
Penkert, Rhiannon R; Hurwitz, Julia L; Thomas, Paul et al. (2018) Inflammatory molecule reduction with hydroxyurea therapy in children with sickle cell anemia. Haematologica 103:e50-e54
Turner, Benjamin L; Brenes-Arguedas, Tania; Condit, Richard (2018) Pervasive phosphorus limitation of tree species but not communities in tropical forests. Nature 555:367-370
Sadighi, Zsila S; Curtis, Elizabeth; Zabrowksi, Jennifer et al. (2018) Neurologic impairments from pediatric low-grade glioma by tumor location and timing of diagnosis. Pediatr Blood Cancer 65:e27063
Wierdl, Monika; Tsurkan, Lyudmila; Chi, Liying et al. (2018) Targeting ALK in pediatric RMS does not induce antitumor activity in vivo. Cancer Chemother Pharmacol 82:251-263
Pui, Ching-Hon; Liu, Yiwei; Relling, Mary V (2018) How to solve the problem of hypersensitivity to asparaginase? Pediatr Blood Cancer 65:
Mukkada, Sheena; Smith, Cristel Kate; Aguilar, Delta et al. (2018) Evaluation of a fever-management algorithm in a pediatric cancer center in a low-resource setting. Pediatr Blood Cancer 65:
Buchman, Cameron D; Chai, Sergio C; Chen, Taosheng (2018) A current structural perspective on PXR and CAR in drug metabolism. Expert Opin Drug Metab Toxicol 14:635-647
Gibbs, E B; Kriwacki, R W (2018) Direct detection of carbon and nitrogen nuclei for high-resolution analysis of intrinsically disordered proteins using NMR spectroscopy. Methods 138-139:39-46
Howell, Carrie R; Wilson, Carmen L; Ehrhardt, Matthew J et al. (2018) Clinical impact of sedentary behaviors in adult survivors of acute lymphoblastic leukemia: A report from the St. Jude Lifetime Cohort study. Cancer 124:1036-1043
Zamora, Anthony E; Crawford, Jeremy Chase; Thomas, Paul G (2018) Hitting the Target: How T Cells Detect and Eliminate Tumors. J Immunol 200:392-399

Showing the most recent 10 out of 6764 publications